The Latest Cardiac and Vascular News
SAN JOSE, Calif.–(BUSINESS WIRE)–Heart Repair Technologies, Inc. (“HRT” or “Company”), a privately-held medical device company specializing in disruptive mitral and tricuspid valve repair technology to resolve heart valve regurgitation in heart failure patients, today announced that David H. Chung has been appointed Chief Executive Officer (CEO), effective as of October […]
October 28, 2024 (DENVER) – Cleerly, a pioneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in […]
Baltimore, MD (October 24th, 2024) – Sonavex, Inc., a privately held medical device company with ultrasound technologies that deliver quantitative blood flow and other critical vascular data at the point of care, announced the closing of its $15 million Series A-2 financing. The round attracted several new institutional investors, strong […]
ATLANTA, Oct. 24, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes. On that day, the…
MCLEAN, Va., Oct. 24, 2024 /PRNewswire/ — Somatus, the nation’s largest and leading provider of value-based kidney and cardiovascular care, today announced it serves more than 275,000 patients in all 50 states and across all lines of business. The company’s growth is attributed to new…
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company’s common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant.
Aliso Viejo, CA – October 21, 2024 – Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami’s board of directors, and other medical device industry veterans. Okami was launched by medical […]
BOSTON and NEW YORK, Oct. 21, 2024 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Birmingham Heart Clinic (“BHC”) in its partnership with U.S. Heart & Vascular (“USHV”). BHC is a provider of comprehensive…
The Birmingham Heart Clinic partnership represents USHV’s 1st in the state. BIRMINGHAM, Ala., Oct. 18, 2024 /PRNewswire/ — US Heart & Vascular (“USHV”), a national provider of support services to cardiovascular physician practices, has partnered with Birmingham Heart Clinic (“Birmingham…
